Rahbar, Kambiz; Afshar Oromieh, Ali; Jadvar, Hossein; Ahmadzadehfar, Hojjat (2018). PSMA Theranostics: Current Status and Future Directions. Molecular imaging, 17, p. 1536012118776068. SAGE Publications 10.1177/1536012118776068
|
Text
1536012118776068.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (845kB) | Preview |
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine |
UniBE Contributor: |
Afshar Oromieh, Ali |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1536-0121 |
Publisher: |
SAGE Publications |
Language: |
English |
Submitter: |
Sabine Lanz |
Date Deposited: |
01 Feb 2019 15:09 |
Last Modified: |
05 Dec 2022 15:25 |
Publisher DOI: |
10.1177/1536012118776068 |
PubMed ID: |
29873291 |
BORIS DOI: |
10.7892/boris.125616 |
URI: |
https://boris.unibe.ch/id/eprint/125616 |
Actions (login required)
 |
Edit item |